ERBB2 and breast carcinoma: Therefore, this study aimed to explore the pCR rate of HER-2-positive breast cancer in Chinese patients receiving neoadjuvant anti-HER-2 therapy (including chemotherapy and trastuzumab and/or pertuzumab) and whether factors including PNI, SIRI, etc., could predict the pCR rate and postoperative PFS in patients with HER-2-positive breast cancer after receiving neoadjuvant anti-HER-2 therapy and chemotherapy.